IsoTis Orthobiologics
Medical Devices & Tech
2 Goodyear
Irvine, CA 92618 USA
phone: (949) 595-8710
fax: (949) 595-8711
Symbol ISTSF
Exchange OTC
Founded 0
Employees 40
www.isotis.com
Research Sector Medical Devices & Tech
Summary Description
Product development programs in musculoskeletal repair.
Management
Pieter Wolters, President and Chief Executive Officer; Robert J. Morocco, Chief Financial Officer & Corporate Secretary; James P. Abraham, Senior Vice President Sales; John F. Kay, Chief Scientific Officer; Kathe Liljestrand, Vice President Marketing; James W. Poser, Senior Vice President R&D and Chief Technology Officer; Gene B. Reu, Senior Vice President Operations
Ownership
Financials


* numbers in thousands

 
Keywords
reconstruction, orthopedics

Comment | Printable Version | Nov. 01, 2008
If you work for IsoTis Orthobiologics and want to update this profile, click here

Description
IsoTis OrthoBiologics has a product portfolio with several highly innovative and proprietary natural and synthetic bone graft substitutes on the market and several others in development.
Products / Services
Bone graft substitutes, processed allograft products, and genetically engineered bone growth factors.
Market / Customers
As the global population continues to age, and the average level of physical activity grows, the number of orthopaedic procedures which require the use of bone grafts and substitutes will continue to increase. Further, minimally invasive procedures will encourage a greater percentage of the population to seek treatment.
Strategy
With highly complementary product and technology platforms, the new company is set to become a significant global force in orthobiologics, the fastest growing segment of the US$16 billion orthopaedics market. The combined entity expects to sustain continued long-term growth in revenues through immediate development of its innovative orthobiologics pipeline. The companies have already identified a variety of ongoing product development programs that have the potential to lead to breakthrough products in musculoskeletal repair.
Status
In April 2006, IsoTis received 510(k) clearances from the FDA for the use of Accell Connexus and OrthoBlast II in dental indications.


2008-11-20-606